Prestige Consumer Healthcare (NYSE:PBH) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a research report released on Monday morning.

Other analysts have also issued research reports about the stock. Jefferies Financial Group restated a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson restated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $85.25.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $78.09 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare has a fifty-two week low of $57.95 and a fifty-two week high of $86.36. The stock has a fifty day moving average of $80.33 and a two-hundred day moving average of $73.83. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 2.32 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter in the previous year, the company posted $1.07 EPS. The firm’s revenue for the quarter was down .9% on a year-over-year basis. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William P’pool sold 8,987 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after purchasing an additional 8,533 shares in the last quarter. Franklin Resources Inc. increased its stake in Prestige Consumer Healthcare by 4.3% during the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after buying an additional 894 shares during the period. Sanctuary Advisors LLC lifted its holdings in Prestige Consumer Healthcare by 11.0% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock worth $1,244,000 after buying an additional 1,715 shares in the last quarter. Coldstream Capital Management Inc. purchased a new position in Prestige Consumer Healthcare in the 3rd quarter valued at about $205,000. Finally, Geode Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after acquiring an additional 50,961 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.